209 related articles for article (PubMed ID: 18829559)
21. N-terminal globin adducts as biomarkers for formation of butadiene derived epoxides.
Boysen G; Georgieva NI; Upton PB; Walker VE; Swenberg JA
Chem Biol Interact; 2007 Mar; 166(1-3):84-92. PubMed ID: 17084829
[TBL] [Abstract][Full Text] [Related]
22. First-pass metabolism of 1,3-butadiene in once-through perfused livers of rats and mice.
Filser JG; Faller TH; Bhowmik S; Schuster A; Kessler W; Pütz C; Csanády GA
Chem Biol Interact; 2001 Jun; 135-136():249-65. PubMed ID: 11397395
[TBL] [Abstract][Full Text] [Related]
23. 1,3-Butadiene: exposure estimation, hazard characterization, and exposure-response analysis.
Hughes K; Meek ME; Walker M; Beauchamp R
J Toxicol Environ Health B Crit Rev; 2003; 6(1):55-83. PubMed ID: 12587254
[TBL] [Abstract][Full Text] [Related]
24. Estimation of cancer risk caused by environmental chemicals based on in vivo dose measurement.
Törnqvist M; Ehrenberg L
J Environ Pathol Toxicol Oncol; 2001; 20(4):263-71. PubMed ID: 11797835
[TBL] [Abstract][Full Text] [Related]
25. Physiologically based pharmacokinetic modeling of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybutane toxicokinetics in mice and rats.
Sweeney LM; Schlosser PM; Medinsky MA; Bond JA
Carcinogenesis; 1997 Apr; 18(4):611-25. PubMed ID: 9111190
[TBL] [Abstract][Full Text] [Related]
26. 1,3-Butadiene working group report.
Adler ID; Cochrane J; Osterman-Golkar S; Skopek TR; Sorsa M; Vogel E
Mutat Res; 1995 Aug; 330(1-2):101-14. PubMed ID: 7623862
[TBL] [Abstract][Full Text] [Related]
27. 1,3-Butadiene: II. Genotoxicity profile.
Albertini RJ; Carson ML; Kirman CR; Gargas ML
Crit Rev Toxicol; 2010 Oct; 40 Suppl 1():12-73. PubMed ID: 20868267
[TBL] [Abstract][Full Text] [Related]
28. Micronuclei and gene mutations in transgenic big Blue((R)) mouse and rat fibroblasts after exposure to the epoxide metabolites of 1, 3-butadiene.
Erexson GL; Tindall KR
Mutat Res; 2000 Dec; 472(1-2):105-17. PubMed ID: 11113703
[TBL] [Abstract][Full Text] [Related]
29. Cancer risk estimation of genotoxic chemicals based on target dose and a multiplicative model.
Granath FN; Vaca CE; Ehrenberg LG; Törnqvist MA
Risk Anal; 1999 Apr; 19(2):309-20. PubMed ID: 10765407
[TBL] [Abstract][Full Text] [Related]
30. Metabolism of 1,3-butadiene: inhalation pharmacokinetics and tissue dosimetry of butadiene epoxides in rats and mice.
Himmelstein MW; Turner MJ; Asgharian B; Bond JA
Toxicology; 1996 Oct; 113(1-3):306-9. PubMed ID: 8901914
[TBL] [Abstract][Full Text] [Related]
31. Detoxification of olefinic epoxides and nucleotide excision repair of epoxide-mediated DNA damage: Insights from animal models examining human sensitivity to 1,3-butadiene.
Wickliffe JK; Herring SM; Hallberg LM; Galbert LA; Masters OE; Ammenheuser MM; Xie J; Friedberg EC; Lloyd RS; Abdel-Rahman SZ; Ward JB
Chem Biol Interact; 2007 Mar; 166(1-3):226-31. PubMed ID: 16730686
[TBL] [Abstract][Full Text] [Related]
32. PBPK model for butadiene metabolism to epoxides: quantitative species differences in metabolism.
Johanson G; Filser JG
Toxicology; 1996 Oct; 113(1-3):40-7. PubMed ID: 8901881
[TBL] [Abstract][Full Text] [Related]
33. Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: global sensitivity analysis for experimental design issues.
Brochot C; Smith TJ; Bois FY
Chem Biol Interact; 2007 May; 167(3):168-83. PubMed ID: 17397815
[TBL] [Abstract][Full Text] [Related]
34. Metabolism and mutagenicity of isoprene.
Gervasi PG; Longo V
Environ Health Perspect; 1990 Jun; 86():85-7. PubMed ID: 2401275
[TBL] [Abstract][Full Text] [Related]
35. Cancer risk assessment for 1,3-butadiene: dose-response modeling from an epidemiological perspective.
Sielken RL; Valdez-Flores C; Gargas ML; Kirman CR; Teta MJ; Delzell E
Chem Biol Interact; 2007 Mar; 166(1-3):140-9. PubMed ID: 16876150
[TBL] [Abstract][Full Text] [Related]
36. 1,3-Butadiene: Biomarkers and application to risk assessment.
Swenberg JA; Bordeerat NK; Boysen G; Carro S; Georgieva NI; Nakamura J; Troutman JM; Upton PB; Albertini RJ; Vacek PM; Walker VE; Sram RJ; Goggin M; Tretyakova N
Chem Biol Interact; 2011 Jun; 192(1-2):150-4. PubMed ID: 20974116
[TBL] [Abstract][Full Text] [Related]
37. A measure of tumorigenic potency incorporating dose-response shape.
Meier KL; Bailer AJ; Portier CJ
Biometrics; 1993 Sep; 49(3):917-26. PubMed ID: 8241378
[TBL] [Abstract][Full Text] [Related]
38. Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates.
Kohn MC; Melnick RL
Toxicology; 1996 Oct; 113(1-3):31-9. PubMed ID: 8901880
[TBL] [Abstract][Full Text] [Related]
39. Biomonitoring of 1,3-butadiene and related compounds.
Osterman-Golkar S; Bond JA
Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):907-15. PubMed ID: 8933033
[TBL] [Abstract][Full Text] [Related]
40. Cancer risk estimation of glycidol based on rodent carcinogenicity studies, a multiplicative risk model and in vivo dosimetry.
Aasa J; Granath F; Törnqvist M
Food Chem Toxicol; 2019 Jun; 128():54-60. PubMed ID: 30914355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
